Form 4: NovoCure Director Gabriel Leung Receives Equity Grant

Director Gabriel Leung was granted 11,610 restricted stock units and 16,999 stock options by NovoCure Ltd.

Summary

• Director Gabriel Leung acquired 11,610 restricted stock units (RSUs) on June 3, 2026.
• Director Gabriel Leung was granted 16,999 stock options with an exercise price of $16.15 on June 3, 2026.
• The RSUs and options are scheduled to vest on the earlier of the first anniversary of the grant date or the day before the 2027 annual general meeting.
• Following these transactions, the director's total beneficial ownership of ordinary shares is 101,109.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding standard director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant.

Risks

• None identified; this is a standard compensatory equity grant.

Future Outlook

The equity grants are subject to standard vesting schedules tied to the 2027 annual general meeting or the first anniversary of the grant.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard corporate governance practices designed to incentivize long-term oversight and alignment with shareholder interests in the medical technology sector.

Comparison to Industry Standards

• The grant structure follows standard industry practices for non-employee director compensation in the biotechnology and medical device sectors.

Stakeholder Impact

• Minimal impact on shareholders; reflects standard director compensation practices.

Next Steps

• Vesting of equity grants on or before the 2027 annual general meeting.

Key Dates

Keywords

NovoCure, NVCR, Form 4, Insider Trading, Equity Compensation, Director Compensation